Full text
Earnings transcript
Read the complete earnings call transcript.
CL
Colgate-Palmolive Company
$85.14
-0.27
(-0.32%)
| Exchange: | NYSE |
| Market Cap: | 68.244B |
| Shares Outstanding: | 929.712M |
About The Company
| Sector: | Consumer Defensive | |||||
| Industry: | Household & Personal Products | |||||
| CEO: | Noel R. Wallace | |||||
| Full Time Employees: | 34000 | |||||
| Address: |
| |||||
| Website: | https://www.colgatepalmolive.com |
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom’s of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill’s Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill’s Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 19,457,000 | 20,101,000 | 20,382,000 |
| Gross Profit | 11,251,000 | 12,106,000 | 12,251,000 |
| EBITDA | 4,246,000 | 4,853,000 | 3,956,000 |
| Operating Income | 4,131,000 | 4,383,000 | 4,348,000 |
| Net Income | 2,300,000 | 2,889,000 | 2,132,000 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 16,393,000 | 16,046,000 | 16,330,000 |
| Total Liabilities | 15,436,000 | 15,502,000 | 15,965,000 |
| Total Stockholders Equity | 609,000 | 212,000 | 54,000 |
| Total Debt | 9,064,000 | 8,512,000 | 7,988,000 |
| Cash and Cash Equivalents | 966,000 | 1,096,000 | 1,288,000 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 3,745,000 | 4,107,000 | 4,198,000 |
| Capital Expenditure | -705,000 | -561,000 | -564,000 |
| Free Cash Flow | 3,040,000 | 3,546,000 | 3,634,000 |
| Net Income | 2,455,000 | 3,049,000 | 2,132,000 |
| Net Change in Cash | 191,000 | 130,000 | 192,000 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 23,761,399.016 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 24,391,868.211 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 24,059,733.890 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 4,743,349.084 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 4,869,205.961 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 4,802,903.929 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 3,890,660.151 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 4,025,367.639 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 3,954,404.500 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 8,660,185.396 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 8,889,969.009 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 8,768,917.854 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 4.880 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 4.960 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 4.800 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 5 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 2 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Robust Revenue Performance: CL demonstrates strong revenue figures as reflected in the latest income statements, with consistent growth in key product categories as per revenue product segments data. This indicates a solid market position within its industry.
- Healthy Cash Flow Metrics: The cash flow statements highlight a strong net cash provided by operating activities and positive free cash flow, suggesting operational efficiency and the ability to fund growth initiatives without excessive reliance on external financing.
- Favorable Valuation Metrics: The current price-to-earnings (P/E) ratio and price-to-sales (P/S) ratio from key metrics indicate that CL is reasonably valued compared to industry averages, potentially appealing to value-focused investors.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates CL intrinsic value between $63.44 – $93.21 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about CL valuation
Is Colgate-Palmolive Company (CL) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Colgate-Palmolive Company (CL) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is CL a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether CL trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is CL’s P/E ratio?
You can see CL’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for CL?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is CL a good long-term investment?
Whether CL fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
CL
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
-0.32
Trading Metrics:
| Open: | 85.33 | Previous Close: | 85.41 | |
| Day Low: | 84.43 | Day High: | 85.39 | |
| Year Low: | 74.55 | Year High: | 99.33 | |
| Price Avg 50: | 90.95 | Price Avg 200: | 84.41 | |
| Volume: | 3.25M | Average Volume: | 6.709M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeCL full analysis
Welcome to MARKETSNAP’s SWOT analysis for Colgate-Palmolive Company, or CL as it’s known on the ticker. If you’re a long-term investor looking to build wealth with solid picks, you’re in the right place. Today, we’re diving deep into Colgate-Palmolive, a household name in personal care and consumer goods, to break down what makes this company tick and whether it’s a worthy addition to your portfolio. Let’s unpack the latest developments, crunch some numbers, and lay out the strengths, weaknesses, opportunities,…
